Art. -Nr.: HY-W015309

Decanoic acid

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 334-48-5
Formel: C₁₀H₂₀O₂
Molecular Weight:172.27

Speicherung:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Decanoic acid Chemical Structure

CAS. Nr.: 334-48-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

AMPA Receptor

Human Endogenous Metabolite

Alle iGluR Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	30 μM Compound: 1	Agonist activity at recombinant human N-terminally HA-tagged GPR84 expressed in CHO cells co-expressing Gqi5 assessed as inhibition of forskolin-induced cAMP accumulation by fluo-4AM dye based FLIPR assay Agonist activity at recombinant human N-terminally HA-tagged GPR84 expressed in CHO cells co-expressing Gqi5 assessed as inhibition of forskolin-induced cAMP accumulation by fluo-4AM dye based FLIPR assay	[PMID: 31721581]
CHO	EC₅₀	4.6 μM Compound: 1	Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by liquid scintillation counting method Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by liquid scintillation counting method	[PMID: 31721581]
CHO	EC₅₀	4.6 μM Compound: 1	Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production preincubated for 20 mins followed by forskolin addition and measured after 20 mins Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production preincubated for 20 mins followed by forskolin addition and measured after 20 mins	[PMID: 31721581]
CHO	EC₅₀	48 μM Compound: 1	Agonist activity at recombinant human GPR84 expressed in CHO cells co-expressing Galpha16/Gqs5/Gqo5/Gqi9 assessed as increase in calcium mobilization measured for 20 secs in presence of coelenterazine by aequorin-reporter gene based luminescence assay Agonist activity at recombinant human GPR84 expressed in CHO cells co-expressing Galpha16/Gqs5/Gqo5/Gqi9 assessed as increase in calcium mobilization measured for 20 secs in presence of coelenterazine by aequorin-reporter gene based luminescence assay	[PMID: 31721581]
HEK293	EC₅₀	10 μM Compound: 1	Agonist activity at recombinant human GPR84 expressed in HEK293 cells assessed as beta-arrestin 2 recruitment by beta-galactosidase based PathHunter assay Agonist activity at recombinant human GPR84 expressed in HEK293 cells assessed as beta-arrestin 2 recruitment by beta-galactosidase based PathHunter assay	[PMID: 31721581]
MONO-MAC-6	IC₅₀	>200 μM Compound: Decanoic acid	Cytostatic activity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytostatic activity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28384546]
Sf9	EC₅₀	48 μM Compound: 1	Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 30 mins by liquid scintillation counting method Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 30 mins by liquid scintillation counting method	[PMID: 31721581]

In Vitro

Decanoic acid (60 μM, 1 h or 24 h) targets mTORC1 independent of PI3K/AKT, AMPK signaling and inhibits mTORC1 without altering mTORC2 activation , also reduces Ddp97 activity in Dictyostelium^[1].
Decanoic acid (300 μM, 24 h) decreases the ratio of p-4E-BP1/total-4E-BP1 and p-S6K/total-S6K to reduce mTORC1 activity in patient-derived astrocytes with tuberous sclerosis complex^[1].
Decanoic acid (80 μM, 2 h 30 min) reduces the cell viability, suppresses hepatocyte growth factor (HGF)-induced c-Met phosphorylation in both HCCLM3 and HepG2 cells^[2].
Decanoic acid (80 μM, 24 h) triggers apoptosis in HCCLM3, HepG2 and HGF-induced cells^[2].
Decanoic acid (0.3 mM or 1 mM, perfuse, 40 min) is a broad spectrum AMPA receptor inhibitor in a subunit dependent, non-competitive and voltage dependent manner in oocytes expressing a homomeric (GluA1 subunit) and heteromeric (GluA1/2 and GluA2/3) AMPA receptors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Dictyostelium cells
Concentration:

0 - 80 µM
Incubation Time:

50 h
Result:

Decreased p-4E-BP1 levels, but had no significant difference in p-AKT-S and p-AMPK levels at 1 h and 24 h in dictyostelium cells.

Western Blot Analysis^[1]

Cell Line:

Astrocytes derived from patients with tuberous sclerosis complex
Concentration:

300 μM
Incubation Time:

24 h
Result:

Reduced the ratio of p-4E-BP1/total-4E-BP1 and p-S6K/total-S6K in astrocytes derived from control patients and patients with mutations in TSC1.

Cell Viability Assay^[2]

Cell Line:

HCCLM3 and HepG2 cells
Concentration:

0 - 80 µM
Incubation Time:

50 h
Result:

Reduced the cell viability in HGF-induced/uninduced HCC cells.

Western Blot Analysis^[2]

Cell Line:

HCCLM3 and HepG2 cells
Concentration:

80 µM
Incubation Time:

2 h 30 min
Result:

Suppressed constitutive as well as HGF-induced c-Met phosphorylation in both HCCLM3 and HepG2 cells.

Apoptosis Analysis^[2]

Cell Line:

HCCLM3, HepG2 and HGF-induced cells
Concentration:

80 µM
Incubation Time:

24 h
Result:

Downregulated the levels of antiapoptotic proteins such as Bcl-2, Survivin, IAP-1, Cyclin D1, and COX-2 in HCCLM3, HepG2 and HGF-induced cells.

In Vivo

Decanoic acid (100 μM and 300 μM, 1 h) significantly decreases plasma PTH concentration and decreases Cyp24a1 expression in the kidney at higher flow rates. Additionally, Decanoic acid exerts no change in p-AKT(Thr308)/total-AKT or p-AKT(Ser473)/total-AKT in both Dictyostelium and rat hippocampal slices^[1].
Decanoic acid (50 mg/kg, i.p., thrice a week for four weeks) effectively mitigates tumorigenesis without displaying toxicity in HCC mouse model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Rat Hippocampal Slices^[1]
Dosage:

100 μM and 300 μM
Administration:

1 h
Result:

Decreased p-4E-BP1/total-4E-BP1 levels at 300 μM in rat hippocampal slices

Animal Model:

NCr-nude female mice^[2]
Dosage:

5, 50, 100 mg/kg (0.1% DMSO)
Administration:

i.p., measured body weight daily for 8 days
Result:

Caused no substantial effects on body weight and on the levels of various enzymes in the liver and kidney of mice

Animal Model:

HCC mouse model^[2]
Dosage:

50 mg/kg (0.1% DMSO)
Administration:

i.p., thrice a week for four weeks
Result:

Significantly regressed the growth of tumors in the HCC mouse model

Chemical Information

CAS. Nr. 334-48-5
Appearance <27°C Solid,>32°C Liquid
Molecular Weight 172.27
Formel C₁₀H₂₀O₂
Color White to off-white
SMILES

CCCCCCCCCC(O)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Diabetes

Gut Microbiota-Decanoic Acid-Interleukin-17A Axis Orchestrates Hyperglycemia-Induced Osteoporosis in Male Mice. [Abstract]

2025 Oct 27:db250471. PMID: 41144501
Nutrients

Medium-Chain Fatty Acids Selectively Sensitize Cancer Cells to Ferroptosis by Inducing CD36 and ACSL4. [Abstract]

2025 Feb 25;17(5):794. PMID: 40077664
Biochem Biophys Res Commun

Medium-chain fatty acids activate fructose metabolism via up-regulating GLUT5-KHK axis. [Abstract]

2026 Mar 12:804:153358. PMID: 41619507

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 130 mg/mL (754.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.8048 mL

29.0242 mL

58.0484 mL

5 mM

1.1610 mL

5.8048 mL

11.6097 mL

10 mM

0.5805 mL

2.9024 mL

5.8048 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (12.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/1% Tween-80 in Saline water

Solubility: 4.95 mg/mL (28.73 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Boison D, et, al. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017 Apr;30(2):187-192. [Content Brief]

[2]. Warren EC, et al. Decanoic acid inhibits mTORC1 activity independent of glucose and insulin signaling[J]. Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23617-23625. [Content Brief]

[3]. Yang MH, et al. Decanoic Acid Exerts Its Anti-Tumor Effects via Targeting c-Met Signaling Cascades in Hepatocellular Carcinoma Model[J]. Cancers (Basel). 2023 Sep 22;15(19):4681. [Content Brief]

[4]. Chang P, et al. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain. 2016 Feb;139(Pt 2):431-43. [Content Brief]

[5]. Kim S, et, al. Selective production of decanoic acid from iterative reversal of β-oxidation pathway. Biotechnol Bioeng. 2018 May;115(5):1311-1320. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.8048 mL	29.0242 mL	58.0484 mL	145.1210 mL
	5 mM	1.1610 mL	5.8048 mL	11.6097 mL	29.0242 mL
	10 mM	0.5805 mL	2.9024 mL	5.8048 mL	14.5121 mL
	15 mM	0.3870 mL	1.9349 mL	3.8699 mL	9.6747 mL
	20 mM	0.2902 mL	1.4512 mL	2.9024 mL	7.2561 mL
	25 mM	0.2322 mL	1.1610 mL	2.3219 mL	5.8048 mL
	30 mM	0.1935 mL	0.9675 mL	1.9349 mL	4.8374 mL
	40 mM	0.1451 mL	0.7256 mL	1.4512 mL	3.6280 mL
	50 mM	0.1161 mL	0.5805 mL	1.1610 mL	2.9024 mL
	60 mM	0.0967 mL	0.4837 mL	0.9675 mL	2.4187 mL
	80 mM	0.0726 mL	0.3628 mL	0.7256 mL	1.8140 mL
	100 mM	0.0580 mL	0.2902 mL	0.5805 mL	1.4512 mL

Decanoic acid

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Decanoic acid

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Human Endogenous Metabolite Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Food Additive Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Human Metabolite Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Cytokine Inhibitors Library

Ion Channel Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Pesticide Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Amino Acid Metabolism Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mouse Metabolite Compound Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Flavors and Fragrances Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Environmental Pollutant Compound Library

Publications Citing Use of MedChemExpress (MCE) Decanoic acid

Alle iGluR Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation